NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
Clinical Trials
6 trialsNCT01517802 2022-05-10
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Janssen Research & Development, LLC
Phase 3 Completed
NCT01842321 2021-02-23
AMA
UNICANCER
Phase 2 Completed
NCT01381874 2019-04-11
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT00755885 2017-01-26
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer
Cancer Research UK
Phase 1/2 Completed
NCT01814865 2013-12-20
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
British Columbia Cancer Agency
Phase 2 Withdrawn